Accession Number:

ADA592082

Title:

Enhancing Therapeutic Cellular Prostate Cancer Vaccines

Descriptive Note:

Final rept. 15 May 2012-14 May 2013

Corporate Author:

MISSISSIPPI UNIV MEDICAL CENTER JACKSON

Personal Author(s):

Report Date:

2013-06-01

Pagination or Media Count:

98.0

Abstract:

Prostate cancer CaP remains among the most common causes of cancer related deaths in men. Because CaP is characterized by unique prostate associated antigens, it has been considered among prime candidates for immunotherapy. Despite numerous laboratory advances, clinical outcomes have been partial and transient. One plausible reason for the incomplete response is that vaccine cells, prepared under standard tissue culture conditions, can drastically differ in expression of macromolecules in situ, and thus may immunize against a less complete antigen spectrum. The purpose of the proposed studies is to optimize the effectiveness of therapeutic whole cell CaP vaccines by taking into consideration tumor associated hypoxia as a relevant determinant factor of tumor antigenicity.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE